Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer

Cancer Science

Volumn 101, Issue 12, 2010, Pages 2591-2595

  Kusaba, Hitoshi ^a   Esaki, Taito ^b   Futami, Kitaro ^c   Tanaka, Sinnosuke ^d   Fujishima, Hiromitsu ^e   Mitsugi, Kenji ^f   Sakai, Kenji ^g   Ariyama, Hiroshi ^b   Tanaka, Risa ^f   Kinugawa, Naoko ^a   Ueki, Takashi ^a   Mibu, Rhuichi ^a   Baba, Eishi ^a   Nakano, Shuji ^a   Akashi, Koichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c Fukuoka University Chikushi Hospital   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

^f HAMANOMACHI HOSPITAL   (Japan)

^g SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN; SEROTONIN 3 ANTAGONIST; TEGAFUR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; TEGAFUR;

EID: 78449310290     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01728.x     Document Type: Article

References (29)

1. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systemic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321: 531-5.
2. Scheithauer W, Rosen H, Kornek GV et al. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-5.
3. Shimada Y, Yoshino M, Wakui A et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-13.
4. Pavillard V, Formento P, Rostagno P et al. Combination of irinotecan (CPT-11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol 1998; 56: 1315-22.
5. Mullany S, Svingen PA, Kaufmann SH et al. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 1998; 42: 391-9.
6. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: multicentre randomized trial. Lancet 2000; 355: 1041-7.
7. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectalcancer Irinotecan Study Group. N Engl J Med 2000; 343: 905-14.
8. Shirasaka T, Nakano K, Takechi T et al. Antitumor activity of 1M tegafur-0.4M 5-chloro-2, 4-dihydroxypyrimidine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rat. Cancer Res 1996; 56: 2602-6.
9. Ohtsu A, Baba N, Sakata Y et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 2000; 83: 141-5.
10. Shirao K, Ohtsu A, Takada H et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 2004; 100: 2355-61.
11. Van den Brande J, Scho ffski P, Schellens JHM et al. EORTC early clinical studies group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 2003; 88: 648-53.
12. Therasse P, Arbuck SG, Eisenheuer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
13. Mansfield PF, Hohn DC, Fornage BD et al. Complications and failures of subclavian-vein catheterization. N Engl J Med 1994; 331: 1735-8.
14. Zawacki WJ, Walker TG, DeVasher E et al. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. J Vasc Interv Radiol 2009; 20: 624-7.
15. Cassidy J, Clarke S, Díaz-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-12.
16. Porschen R, Arkenau HT, Kubicka S et al. AIO Colorectal Study Group Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217-23.
17. Díaz-Rubio E, Tabernero J, Gómez-España A et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25: 4224-30.
18. Bajetta E, Di Bartolomeo M, Mariani L et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100: 279-87.
19. Patt YZ, Leibmann J, Diamandidis D et al. Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): final safety findings from a phase II trial. (Abstract) J Clin Oncol 2004; 22: 271.
20. Goto A, Yamada Y, Yasui H et al. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2006; 17: 968-73.
21. Komatsu Y, Yuuki S, Fuse N et al. Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: hokkaido Gastrointestinal Cancer Study Group HGCSG0302. Jpn J Clin Oncol 2005; 35: 88-9.
22. Yoshioka T, Kato S, Gamoh M et al. Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. Br J Cancer 2009; 101: 1972-7.
23. Yamada Y, Tahara M, Miya T et al. Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer 2008; 98: 1034-8.
24. Zang DY, Lee BH, Park HC et al. Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 892-6.
25. Tournigand C, Andre' T, Achille E et al. FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
26. Ishikawa T, Sekiguchi F, Fukase Y et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58: 685-90.
27. Ishikawa T, Fukase Y, Yamamoto T et al. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecita-bine). Biol Pharm Bull 1998; 21: 713-7.
28. Naguib FN, Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45: 5405-12.
29. Ueda Y, Yamagishi H, Yamashita T et al. S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study. Jpn J Clin Oncol 2004; 34: 282-6.